GO
Loading...

Medicine

More

  • Roche To Genentech: Deal Or No Deal? Friday, 6 Mar 2009 | 3:06 PM ET

    Yeah, "Deal Or No Deal" has become a bit of a tired cliche, but I think it's totally appropriate in the context of the latest salvo in the Roche-Genentech takeover battle.

  • Merck's Jumpin' Januvia Friday, 6 Mar 2009 | 11:10 AM ET

    Japan and Januvia. No, it's not a country—not even a fictional one—even though it sounds like "Genovia" in "The Princess Diaries." It's a diabetes drug from Merck.

  • Pfizer Gets A Two-Fer Thursday, 5 Mar 2009 | 11:20 AM ET
    Pfizer

    As Pfizer Chairman and CEO Jeff Kindler represents at the White House Healthcare Summit today and tries to make the industry's case against government price controls on prescription drugs, a couple of prominent industry analysts are giving him a little something to smile about.

  • Biopharma's Ma & Pa Wednesday, 4 Mar 2009 | 11:52 AM ET

    Forget about mergers and acquisitions (M & A). Think about partnerships and acquisitions or what Leerink Swann, which specializes in healthcare stock coverage, is calling "P & A."

  • Roche Rallies And Genentech Gains Tuesday, 3 Mar 2009 | 11:43 AM ET

    The morning after Genentech's big investor meeting shares of the Swiss drugmaker Roche rebounded in overseas trading and the American Despository Receipts that trade over-the-counter here in the States are following suit.

  • Biotech Beats Pfizer Friday, 27 Feb 2009 | 3:33 PM ET

    When I wasn't looking the market value of biotech giant DNA surpassed the market cap of the world's biggest drug company, Pfizer.

  • At Genentech Mum's The Word Friday, 27 Feb 2009 | 1:59 PM ET
    Genetech

    I'm not sure why Genentech isn't responding to Roche's media campaign. Maybe the company's and executives' lawyers are telling them to publicly keep their mouths shut outside of formal presentations like Monday's meeting. Or maybe, for whatever reason, they're decidedly taking a hardline "no media" stance and letting their press releases and SEC filings do all the talkin'.

  • Is Biopharma A "Buy"? Friday, 27 Feb 2009 | 11:46 AM ET

    Even though nearly every analyst this morning is saying Thursday's bloodbath was an overreaction, investors are continuing to sell biopharma stocks in the early going Friday.

  • Big Biotech Bloodbath Thursday, 26 Feb 2009 | 4:49 PM ET

    Today was really ugly for biotech.  The only large-cap sector stock to trade higher--and significantly--was Genentech because it's being bolstered by Roche's bond sale and increasing speculation the Swiss drugmaker is gonna have to raise its bid for DNA.

  • No "Jai Ho" For India's Ranbaxy Thursday, 26 Feb 2009 | 12:31 PM ET
    Slumdog Millionaire

    Recently, there've been scattered media reports about some drugs polluting India's slum water in alarming concentrations, according to some experts. Separately, yesterday, the U.S. Food and Drug Administration announced it's keeping India generic drugmaker Ranbaxy in the penalty box while it continues looking into whether the company fudged some data.

  • Pfizer's Unlucky 13-Year Milestone Wednesday, 25 Feb 2009 | 4:02 PM ET

    September 1996. I was in the middle of my nearly 10-year stint at WXYZ-TV in Detroit. And shares of Dow component Pfizer closed at $12.90. February 2009. This year will mark my ninth anniversary (man, time flies) at CNBC. And today PFE hit a new intra-day low of $12.90.

  • New Rx For Big Pharma Wednesday, 25 Feb 2009 | 8:24 AM ET

    Big pharma has to change the way it sells drugs. That's the conclusion of a new PricewaterhouseCoopers report about what the industry will look like in 2020, which calls the big pharma sales model "increasingly ineffective."

  • Pfizer's February Failures Tuesday, 24 Feb 2009 | 11:25 AM ET
    Pfizer

    This morning the world's biggest pharmaceutical firm announced that it's scrapping two more drugs that were in late-stage studies.

  • Generic Drugmakers Are Puttin' On The Ritz Monday, 23 Feb 2009 | 2:26 PM ET
    Ritz Carlton Naples

    At the risk of offending our gracious hosts here at the Generic Pharmaceutical Association's Silver Anniversary Meeting, I wanted to talk about the seemingly incongruous venue for the event.

  • The McDonald's Drug Pipeline & Your Emails Friday, 20 Feb 2009 | 10:00 AM ET

    Is there a pipeline from the C-suite of McDonald's to the ivory towers of biopharma? At least one "Pharma's Market" reader from overseas thinks so.

  • Amgen's Epogen & Pedal Pushers Thursday, 19 Feb 2009 | 8:26 AM ET
    Lance Armstrong

    The "Amgen Tour of California" is getting a lot more publicity than usual because superstar cyclists Lance Armstrong and Floyd Landis are trying to make comebacks in the race.

  • Eli Lilly Super-Sizes Its Board Wednesday, 18 Feb 2009 | 1:39 PM ET

    Yes, McDonald's has done away with "Super-Size" menu items, but I can still use the American lexicon for, hopefully, an attention-grabbing blog headline.

  • BEAT Beats The Street Wednesday, 18 Feb 2009 | 11:08 AM ET

    CardioNet caught my eye and attention when I got a research note from Rick Wise at Leerink Swann about BEAT beating the Street.

  • Stem Cells Sell Tuesday, 17 Feb 2009 | 1:45 PM ET

    Attendance at the 4th Annual Stem Cell Summit is up, by about 50 percent, no less, over last year. All day long privately-held and publicly-traded companies are presenting to around 250 investors.

  • Pfizer, Costco & Glaxo's Ofatumumab Friday, 13 Feb 2009 | 11:37 AM ET

    Friday the 13th. My lucky day for reaching into the Pharma's Market mailbag. Time for your Emails.